EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY 4.0

Glucagon‐like peptide agonists for weight management in antipsychotic‐induced weight gain: A systematic review and meta‐analysis

Maarten Bak, Bea Campforts, Patrick Domen, Therese van Amelsvoort, Marjan Drukker iD

Acta Psychiatrica Scandinavica · 2024-12 · 150 (6) · 516-529

DOI: 10.1111/acps.13734 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta Psychiatrica Scandinavica, online erschienen am 24.07.2024. Verfasst von Maarten Bak und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry & Neuropsychology, Maastricht University, Maastricht, The Netherlands. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Managing body weight in patients with antipsychotic‐induced weight gain (AIWG) is challenging. Besides lifestyle interventions, pharmacological interventions may contribute to weight loss. This systematic review and meta‐analysis evaluated the effect on weight loss and adverse effects of glucagon‐like peptide‐1 (GLP‐1) agonists in patients with AIWG. Materials and Methods Following PRISMA guidelines, we performed a meta‐analysis of blinded and open‐label randomised controlled trials (RCTs), non‐randomised controlled trials and cohort studies that evaluated treatment with GLP‐1 in patients with AIWG, regardless of psychiatric diagnosis. PubMed, Embase, PsycINFO and Cochrane Library databases were searched. Primary outcome measures were changes in body weight and BMI. Secondary outcomes were changes in adverse effects and severity of psychopathology due to GLP‐1 agonists.

Results

Only data for exenatide and liraglutide could be included, that is, five RCTs and one cohort study. For exenatide the mean weight loss was −2.48 kg (95% Confidence Interval (CI) −5.12 to +0.64; p = 0.07), for liraglutide the mean weight loss was −4.70 kg (95% CI −4.85 to −4.56; p < 0.001). The mean change in BMI was −0.82 (95% CI −1.56 to −0.09; p = 0.03) in the exenatide groups and −1.52 (95% CI −1.83 to −1.22; p < 0.001) in the liraglutide groups. Exenatide and liraglutide did not adversely affect psychopathology. The most common adverse events were nausea, vomiting, and diarrhoea.

Conclusion

The GLP‐1 agonists exenatide and liraglutide are promising drugs for inducing weight loss in patients with AIWG. The adverse effects are acceptable, and the addition of GLP‐1 does not increase the severity of psychopathology. However, more research is needed.

Schlagwörter

Stichwörter der Autor:innen

GLP‐1 agonistantipsychoticsanti‐obesity medicationmeta‐analysisobesity

Autor:innen und Institutionen

  • Department of Psychiatry & Neuropsychology, Maastricht University, Maastricht, The Netherlands.
  • Department of FACT and Transition Psychiatry, Mondriaan Mental Health, Maastricht, The Netherlands.

ORCID-Profile: Marjan Drukker

Zitieren

APA

Bak, M., Campforts, B., Domen, P., van Amelsvoort, T., & Drukker, M. (2024). Glucagon‐like peptide agonists for weight management in antipsychotic‐induced weight gain: A systematic review and meta‐analysis. Acta Psychiatrica Scandinavica, 150(6), 516-529. https://doi.org/10.1111/acps.13734

Vancouver

Bak M, Campforts B, Domen P, van Amelsvoort T, Drukker M. Glucagon‐like peptide agonists for weight management in antipsychotic‐induced weight gain: A systematic review and meta‐analysis. Acta Psychiatrica Scandinavica. 2024;150(6):516-529. doi:10.1111/acps.13734

BibTeX
@article{Bak2024,
  author = {Bak, Maarten and Campforts, Bea and Domen, Patrick and van Amelsvoort, Therese and Drukker, Marjan},
  title = {Glucagon‐like peptide agonists for weight management in antipsychotic‐induced weight gain: A systematic review and meta‐analysis},
  journal = {Acta Psychiatrica Scandinavica},
  year = {2024},
  volume = {150},
  number = {6},
  pages = {516--529},
  doi = {10.1111/acps.13734}
}
Kostenlos starten →